



**ASX Announcement**

**19 May 2011**

## **Resignation of Director**

**SYDNEY Australia, 19 May 2011:** Sunshine Heart, Inc. (ASX: SHC), today announced the resignation of Mr John Brennan from its board of directors. The Chairman, Nicholas Callinan, on behalf of the board thanked Mr Brennan for his significant contribution to the company's development in the crucial years since his appointment in 2006. He said: "in a small, rapidly growing company like Sunshine Heart, the directors are more intimately involved in the company's operations than in larger businesses. John's extensive commercial experience and judgment has been most valuable to the company. We wish him well for the future." Mr Brennan's resignation was for personal reasons.

### **About Sunshine Heart**

Sunshine Heart (ASX: SHC) is a global medical device company committed to the commercialization of the C-Pulse® Heart Assist System, an implantable, non-blood contacting, heart assist therapy for the treatment of moderate to severe heart failure which can be implanted using a minimally invasive procedure. C-Pulse is designed to relieve the symptoms of heart failure through the use of counter-pulsation technology by enabling an increase in cardiac output, an increase in coronary blood flow, and a reduction in the heart's pumping load. The company has received approval from the U.S. Food and Drug Administration to conduct a U.S. feasibility clinical trial with the C-Pulse System. Sunshine Heart is a Delaware-based corporation headquartered in Minneapolis, MN, with a subsidiary presence in Australia. The company has been listed on the ASX since September 2004. For more information, please visit [www.sunshineheart.com](http://www.sunshineheart.com).

For more information please contact:

Dave Rosa  
CEO Sunshine Heart  
+ 1 (952) 345-4201  
[dave.rosa@sunshineheart.com](mailto:dave.rosa@sunshineheart.com)

Andrew Geddes  
CoActive Health Communications  
+ 61 2 9555 4453 or 0408 677 734